**Supplementary Figure 1:** The flowchart of grouping of enrolled HBsAg positive subjects. Non/mild fibrosis group: ALT ≤40 U/L, LSM ≤9.0 kPa or ALT >40 U/L, LSM ≤9.4 kPa; Significant/advanced fibrosis group: ALT ≤40 U/L, 9.0 ≤ LSM < 12.0 kPa (advanced liver fibrosis) or ALT >40 U/L, 9.4 ≤ LSM < 12.4 (significant liver fibrosis) and 12.4 ≤LSM< 17.0 kPa (advanced liver fibrosis, [ALT < 2\*ULN, 10.6 ≤LSM< 17.0 kPa]); Cirrhosis group: ALT ≤40 U/L, LSM ≥12.0 kPa or ALT >40 U/L, LSM ≥17.0 kPa. 10 cases patients were not grouped for liver fibrosis due to ALT ≥200 U/L or TBIL ≥ 51 μmol/L, but these patients still required antiviral therapy. ALT: Alanine aminotransferase; HBV: Hepatitis B virus; LSM: Liver stiffness measurement; TBIL: Total bilirubin.

1529 cases of chronic HBV infection in community population

Fibrosis stage measured by LSM *n* = 1519

ALT ≥ 200U/L or TBil ≥ 51μmol/L *n* = 10

Cirrhosis *n* = 68

Non/mild fibrosis *n* = 1246

Significant/advanced fibrosis *n* = 205

HBV DNA＜20 IU/mL

*n* = 168

ALT ≤ 40U/L

*n* = 939

ALT＞40U/L

*n* = 139

HBV DNA ≥ 20 IU/mL

*n* = 1078

Antiviral therapy be needed

*n* = 422

Antiviral therapy not needed

*n* = 1107